Mersana Therapeutics Announces Changes in Leadership
06 sept. 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
08 août 2023 08h00 HE
|
Mersana Therapeutics, Inc.
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan commitments into 2026 CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
27 juil. 2023 07h06 HE
|
Mersana Therapeutics, Inc.
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
15 juin 2023 07h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juin 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Upcoming Investor Conferences
24 mai 2023 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
09 mai 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023Advanced enrollment in Phase 3 UP-NEXT clinical trial...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mai 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...